MedTrace Logo

Medication Use Evaluation for Enoxaparin in Hospitalized COVID-19 Patients

NCT05226793 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2025-07-28

No results posted yet for this study

Summary

Retrospective chart review to be conducted at Methodist Richardson Medical Center (MRMC) in Richardson, TX. All adult patients hospitalized with COVID-19 on enoxaparin for DVT prophylaxis will be included. Collected data will be analyzed to determine the safety and effectiveness of the varying enoxaparin doses, and results will be presented at the American Society of Health-System Pharmacists Midyear conference in December 2022.

Conditions

  • Venous Thromboembolism

Sponsors & Collaborators

  • Methodist Health System

    lead OTHER

Principal Investigators

  • Betina Daniel, PharmD · Methodist

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-17
Primary Completion
2025-07-22
Completion
2025-07-22

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05226793 on ClinicalTrials.gov